Cancer

Title
The Study of an Investigational Medication PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Two Standard Chemotherapy Agents or the Standard Chemotherapy Agents Alone in Patients with Stage IV Previously Untreated Pancreatic Cancer
Trial Number
205475071713
Number of Participants
132
Principal Investigator

Shelly Lo

M.D., ABIM
Hematology/Oncology
Associate Professor
Eligibility

Participants must be 18 years old or older with histologically confirmed Stage IV pancreatic ductal adenocarcinoma (PDA) with documented disseminated neoplasm to the liver and/or the lung; one or more metastatic tumors measurable on computed tomography (CT) scan per RECIST v1.1 criteria, excluding the primary pancreatic lesion; tumor tissue must be available for evaluation; FNA not acceptable; no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease; has life expectancy = three months, Karnofsky Performance Status = 70 percent.

Purpose

The purpose of this study is to find out more about how the experimental drug PEGPH20 combined with nab-Paclitaxel plus Gemcitabine compares with nab-Paclitaxel plus Gemcitabine alone in the treatment of Stage IV previously untreated pancreatic cancer.

Enrollment

(708) 327-2831

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.